ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC | VuMedi

ASCO 2022 Conference Coverage

ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC

By ASCO 2022 Conference Coverage FEATURING Virginia Kaklamani

By ASCO 2022 Conference Coverage FEATURING Virginia Kaklamani

290 views

June 10, 2022

Comments 0

Login to view comments. Click here to Login